About this Research Topic
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) describes a growing and complex health concern that has garnered significant attention in recent years. This disease, frequently associated with obesity, type 2 diabetes, and metabolic dysregulation, is characterized by indolent hepatic fat storage, which can lead to inflammation, fibrosis, and eventually progress to cirrhosis. MASLD has emerged as a significant global health burden, with increasing prevalence rates observed in developed and developing countries. Understanding MASLD is essential due to its potential to progress to severe liver disease and its association with significant morbidity and mortality. It is crucial to adopt a comprehensive approach incorporating pharmacological and nonpharmacological strategies to address this condition.
Pharmacological interventions and nonpharmacological practices for MASLD include common drugs like antihyperlipidemic or glucose-lowering molecules, lifestyle modifications, and dietary interventions. These approaches focus on managing the underlying metabolic risk factors, such as obesity and insulin resistance, which are strongly linked to the development and progression of MASLD. Lifestyle modifications often play a pivotal role in the early management and prevention of MASLD.
This Research Topic aims to bridge the gap in our understanding of MASLD by exploring the current state of pharmacological and nonpharmacological practices to improve the management and outcomes of individuals affected by MASLD. Objectives include a detailed study of MASLD pathophysiology, focusing on the impact of metabolic dysfunction on liver steatosis and inflammation, and examining the disease risk factors and links to metabolic disorders like diabetes and obesity. A critical goal is to address the diagnostic challenges in MASLD, evaluating existing methods and the need for more accurate biomarkers and effective imaging techniques. This article collection also prioritizes exploring and critically analyzing current treatment strategies. This comprehensive examination will provide insights into the multifaceted approach required to address this complex liver disease effectively.
Researchers and clinicians are encouraged to submit original research articles, reviews, mini-reviews, systematic reviews, clinical trials, perspectives, methods, and opinion articles illuminating various aspects of MASLD, specifically focusing on existing pharmacological and nonpharmacological approaches and treatments. We are particularly interested in studies that delve into:
- the pathophysiology of MASLD, including investigations into how metabolic dysfunction contributes to liver steatosis and inflammation
- the epidemiological links between MASLD and other metabolic disorders such as diabetes and obesity, shedding light on the intricate interplay between these conditions
- the diagnostic challenges associated with MASLD, the evaluation of the current diagnostic tools, and the proposal of novel biomarkers or advanced imaging techniques for early detection and assessment of MASLD
- current pharmacological and nonpharmacological interventions, lifestyle modifications, and dietary interventions aimed at effectively managing and mitigating the impact of MASLD
Pharmacological interventions and nonpharmacological practices for MASLD include common drugs like antihyperlipidemic or glucose-lowering molecules, lifestyle modifications, and dietary interventions. These approaches focus on managing the underlying metabolic risk factors, such as obesity and insulin resistance, which are strongly linked to the development and progression of MASLD. Lifestyle modifications often play a pivotal role in the early management and prevention of MASLD.
This Research Topic aims to bridge the gap in our understanding of MASLD by exploring the current state of pharmacological and nonpharmacological practices to improve the management and outcomes of individuals affected by MASLD. Objectives include a detailed study of MASLD pathophysiology, focusing on the impact of metabolic dysfunction on liver steatosis and inflammation, and examining the disease risk factors and links to metabolic disorders like diabetes and obesity. A critical goal is to address the diagnostic challenges in MASLD, evaluating existing methods and the need for more accurate biomarkers and effective imaging techniques. This article collection also prioritizes exploring and critically analyzing current treatment strategies. This comprehensive examination will provide insights into the multifaceted approach required to address this complex liver disease effectively.
Researchers and clinicians are encouraged to submit original research articles, reviews, mini-reviews, systematic reviews, clinical trials, perspectives, methods, and opinion articles illuminating various aspects of MASLD, specifically focusing on existing pharmacological and nonpharmacological approaches and treatments. We are particularly interested in studies that delve into:
- the pathophysiology of MASLD, including investigations into how metabolic dysfunction contributes to liver steatosis and inflammation
- the epidemiological links between MASLD and other metabolic disorders such as diabetes and obesity, shedding light on the intricate interplay between these conditions
- the diagnostic challenges associated with MASLD, the evaluation of the current diagnostic tools, and the proposal of novel biomarkers or advanced imaging techniques for early detection and assessment of MASLD
- current pharmacological and nonpharmacological interventions, lifestyle modifications, and dietary interventions aimed at effectively managing and mitigating the impact of MASLD
Keywords: metabolic dysfunction-associated steatotic liver disease, MASLD, clinical care practice, pharmacological approach, nonpharmacological approach, lifestyle modification
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
